MA-IMABIOTECH
ImaBiotech Group today announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc. Colorado Springs and Salt Lake City sites. The integration of the expertise, innovation and analytical platforms of the companies to form a leading global bioanalytical services provider will provide a unique offering to pharmaceutical and cosmetic companies.
Encompassing unique proprietary drug and biomarker imaging (Mass Spectrometry Imaging), multi-omics, spatialomics capabilities and well-established high performance bioanalytical GLP services, the combined platforms will offer access to a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV. These services reduce the rate of failure and accelerate the development of safer therapies. In conjunction to the operation, the company received a majority investment from ArchiMed SAS (“Archimed”), a leading private equity fund focused on the healthcare sector.
This deal enables a continuing commitment to further extend these specialized capabilities, creating a major player focused exclusively on bioanalytical excellence where the deep-science paradigm, a relentless focus on customer service, and innovative proprietary technology will enable and accelerate therapeutic innovation for our clients.
“I am very pleased to expand our activities in North America and Europe with Pyxant Labs and Archimed,” said former founder and CEO of ImaBiotech, Jonathan Stauber, PhD. “Archimed brings exceptional healthcare expertise with insight into advanced bioanalytical services, and the combination of Pyxant Labs’ established bioanalytical capabilities with ImaBiotech’s innovative imaging technologies will provide a unique service offering to our customers in the US, Europe and Asia, representing a tremendous opportunity to grow in the CRO market.”
“ImaBiotech’s deep-science paradigm and focus on customer service were two essential characteristics in common with our business paradigms, which motivated us toward this combination,” commented Maurice Gaubatz, CEO of Pyxant Labs. "Joining forces with Jonathan’s organization bridges ImaBiotech’s unique mass spectrometry imaging capabilities with Pyxant Labs’ regulatory development bioanalytical services and provides coverage from early research through Phase IV development. The combined enterprise creates an international footprint and leading standing among CROs exclusively focused on mass spectrometry bioanalytical excellence.”
The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2021.
About ImaBiotech www.imabiotech.com
ImaBiotech is a bioanalytical CRO with facilities in Boston (MA, USA) and Lille (Eurasante Park, France). ImaBiotech combines innovative mass spectrometry imaging and spatial biology (histology, multi-omics, spatialomics) techniques in order to decipher the complexity of drug activities. The combination of unique capabilities with advanced digital pathology tools makes possible the measurement of drug activity and drug response, simultaneously, at the single cell level. This performance enables comprehensive drug efficacy evaluation from preclinical to clinical stages.
About Pyxant Labs www.pyxant.com
Founded in 2000, Pyxant Labs provides innovative bioanalytical solutions for advancing leading-edge and challenging drug development programs from translation through NDA approval. Utilizing high resolution mass spectrometry and traditional LC-MS/MS platforms, the Colorado Springs site is recognized for its fast-turnaround drug discovery services, unique expertise quantitating delivery mechanisms for RNA therapeutics, anticipatory customer service, and superior regulatory compliance.
About ArchiMed www.archimed-group.eu
ArchiMed is a leading private equity firm focused exclusively on the healthcare industry. ArchiMed’s strategy is based upon healthcare specialization, integrated private equity, medical and operating expertise, and its unique trans-Atlantic platform that supports growth through internationalization. Over the last 20 years, ArchiMed’s leadership team has directly managed and invested in over 40 small to large-size healthcare companies globally, representing over €5 billion of invested capital. ArchiMed currently manages nearly €2 billion in assets across four funds, small-cap focused MED I and MED II, gene & cell therapy focused PolyMED and mid-cap-focused MED Platform I. The latter is Europe’s largest healthcare fund at €1 billion. ArchiMed is an impact investor and a signatory of the Principles for Responsible Investment , pledged to uphold the United Nations’ Sustainable Development Goals .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005490/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 22:24:00 CEST | Press release
The Company generated net sales of $45.0 million for the quarter and $158.4 million for the yearIncome before income taxes of $5.3 million for the quarter and $18.5 million for the yearBacklog of $138.1 million at January 31, 2025, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest
IFF Declares Dividend for Second Quarter 20251.5.2025 22:15:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/
Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 22:01:00 CEST | Press release
First Quarter Financial Highlights Include: Gross margin of 61.0% compared to 59.8% in the prior year Net Income of $3.4 million compared to $1.3 million in the prior year Billings of $79.4 million, up 7.2% year over year Adjusted EBITDA of $15.3 million compared to $10.7 million in the prior year Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same per
Textron Aviation Calls on Cessna, Beechcraft and Hawker Owners to Transport Athletes to the 2026 Special Olympics USA Games1.5.2025 17:31:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. The company is calling on Cessna, Beechcraft and Hawker aircraft owners and operators to come together on Friday, June 19, 2026, and Saturday, June 27, 2026, to enable champions from all corners of the nation to travel to and from the host city, regardless of financial or logistical challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430812758/en/ Textron Aviation Inc. announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. (Photo credit: Textron Aviation) The Special Oly
Giovanni Brienza Appointed President of Frontline International1.5.2025 17:16:00 CEST | Press release
Longtime leader to guide day-to-day operations Frontline International, celebrating 25 years of innovation in commercial kitchen solutions, has appointed Giovanni Brienza as its new president. Founder John Palazzo will continue as CEO, focusing on strategic direction and long-term growth initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501026483/en/ Giovanni Brienza, Frontline International President Frontline is a USA-based manufacturer of systems used globally by foodservice operations for safer, more sustainable fat, oil, and grease (FOG) management. The company’s automated solutions increase kitchen safety. Brienza, who joined Frontline in 2004, brings 21 years of operational expertise and engineering insight to his new role. He has been a key architect behind many of Frontline’s most impactful innovations, from equipment and software systems to strategically expanding the company’s footprint into key inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom